LMTX (TRx0237)

tau aggregation inhibitor; methylthionininium derivative · TauRx Therapeutics Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LMTX (TRx0237), covering 2024-09-27 to 2024-09-27. Get the full timeline:

Most recent: Clinical Trial Update: TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease